Free Trial
NASDAQ:LBPH

Longboard Pharmaceuticals (LBPH) Stock Price, News & Analysis

Longboard Pharmaceuticals logo
$59.72
+0.02 (+0.03%)
(As of 10/31/2024 ET)

About Longboard Pharmaceuticals Stock (NASDAQ:LBPH)

Key Stats

Today's Range
$59.65
$59.75
50-Day Range
$27.58
$59.70
52-Week Range
$3.60
$59.79
Volume
707,869 shs
Average Volume
1.14 million shs
Market Capitalization
$2.32 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$59.56
Consensus Rating
Hold

Company Overview

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.

Longboard Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
33rd Percentile Overall Score

LBPH MarketRank™: 

Longboard Pharmaceuticals scored higher than 33% of companies evaluated by MarketBeat, and ranked 830th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Longboard Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 4 buy ratings, 5 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Longboard Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Longboard Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Longboard Pharmaceuticals are expected to decrease in the coming year, from ($2.19) to ($2.80) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Longboard Pharmaceuticals is -27.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Longboard Pharmaceuticals is -27.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Longboard Pharmaceuticals has a P/B Ratio of 35.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Longboard Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    15.34% of the float of Longboard Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Longboard Pharmaceuticals has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Longboard Pharmaceuticals has recently decreased by 3.90%, indicating that investor sentiment is improving.
  • Dividend Yield

    Longboard Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Longboard Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    15.34% of the float of Longboard Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Longboard Pharmaceuticals has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Longboard Pharmaceuticals has recently decreased by 3.90%, indicating that investor sentiment is improving.
  • News Sentiment

    Longboard Pharmaceuticals has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Longboard Pharmaceuticals this week, compared to 4 articles on an average week.
  • Search Interest

    Only 8 people have searched for LBPH on MarketBeat in the last 30 days. This is a decrease of -27% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added Longboard Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Longboard Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,090,010.00 in company stock.

  • Percentage Held by Insiders

    Only 4.64% of the stock of Longboard Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    63.28% of the stock of Longboard Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Longboard Pharmaceuticals' insider trading history.
Receive LBPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Longboard Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LBPH Stock News Headlines

Ex WH Advisor Who Predicted Biden Leaving Race Makes Startling New Prediction
Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.
See More Headlines

LBPH Stock Analysis - Frequently Asked Questions

Longboard Pharmaceuticals' stock was trading at $6.03 at the beginning of 2024. Since then, LBPH shares have increased by 890.4% and is now trading at $59.72.
View the best growth stocks for 2024 here
.

Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) announced its earnings results on Thursday, August, 1st. The company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by $0.10.

Longboard Pharmaceuticals (LBPH) raised $75 million in an initial public offering on Friday, March 12th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Evercore ISI, Guggenheim Securities and Cantor served as the underwriters for the IPO.

Longboard Pharmaceuticals' top institutional investors include Emerald Advisers LLC (1.76%), Emerald Mutual Fund Advisers Trust (1.08%) and SG Americas Securities LLC (0.03%). Insiders that own company stock include Randall Kaye and Arena Pharmaceuticals Inc.
View institutional ownership trends
.

Shares of LBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Longboard Pharmaceuticals investors own include JPMorgan Chase & Co. (JPM), Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Visa (V) and Home Depot (HD).

Company Calendar

Last Earnings
8/01/2024
Today
10/31/2024
Next Earnings (Estimated)
11/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LBPH
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$59.56
High Stock Price Target
$90.00
Low Stock Price Target
$32.00
Potential Upside/Downside
-0.3%
Consensus Rating
Hold
Rating Score (0-4)
2.44
Research Coverage
9 Analysts

Profitability

Net Income
$-54,420,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.67 per share

Miscellaneous

Free Float
37,095,000
Market Cap
$2.32 billion
Optionable
Optionable
Beta
1.22
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

This page (NASDAQ:LBPH) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners